VIVESTO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.285 SEK | -1.55% |
|
-9.52% | -30.06% |
| 03-26 | Transcript : Vivesto AB - Special Call | |
| 03-07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
| Sales 2021 | 28.87M 2.64M 211M | Sales 2022 | 3.04M 278K 22.24M | Capitalization | 234M 21.34M 1.71B |
|---|---|---|---|---|---|
| Net income 2021 | -133M -12.16M -973M | Net income 2022 | -357M -32.63M -2.61B | EV / Sales 2021 | 37.7 x |
| Net cash position 2021 | 86.84M 7.94M 635M | Net cash position 2022 | 134M 12.28M 983M | EV / Sales 2022 | 32.6 x |
| P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivesto AB
More press releases
| 1 day | -1.55% | ||
| 1 week | -9.52% | ||
| Current month | -8.21% | ||
| 1 month | -10.80% | ||
| 3 months | -15.43% | ||
| 6 months | +31.34% | ||
| Current year | -30.06% |
1 week
0.28
0.32
1 month
0.280.32
Current year
0.260.55
1 year
0.160.91
3 years
0.163.56
5 years
0.1611.45
10 years
0.1624.40
| Managers | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 22/01/23 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 30/11/20 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 28/02/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 44 | 18/03/19 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 25/09/19 |
Pål Ryfors
BRD | Director/Board Member | 41 | 24/05/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.285 | -1.55% | 492,006 |
| 25/04/24 | 0.2895 | -0.86% | 714,025 |
| 24/04/24 | 0.292 | -4.89% | 653,642 |
| 23/04/24 | 0.307 | -0.32% | 260,389 |
| 22/04/24 | 0.308 | -2.22% | 679,297 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:24 pm
More quotes
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Sector
Pharmaceuticals
Calendar
22/05/2024
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.06% | 13.99M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- VIVE Stock
